MedPage Today |
Biologic Eases Subset of Severe Asthma
MedPage Today For severe eosinophilic asthma, the novel monoclonal antibody mepolizumab cut exacerbations whether given as an injection or infusion and reduced steroid use in patients dependent on them, two trials showed. The drug, which targets interleukin-5 (IL-5 … A respiratory expert undermines GSK's case for new asthma drug mepolizumab Glaxo asthma drug successful in clinical trials (GSK) GSK reports positive Phase III results of its mepolizumab in asthma |
View full post on asthma – Google News